Last updated: July 10, 2026
Sanofi-Aventis U.S. LLC v. Eli Lilly and Company (1:14-cv-00113): Litigation Summary, Patent-Use Analysis, and Exclusivity/Entry Implications
Executive summary: The docket 1:14-cv-00113 in the US federal courts is a patent infringement dispute between Sanofi-Aventis U.S. LLC and Eli Lilly and Company. A complete litigation summary requires specific docket records (claims, asserted patents, rulings, settlement, and final judgment). Those case specifics are not available in the provided information, so no accurate patent, timeline, or disposition analysis can be produced.
What patents were asserted in Sanofi-Aventis U.S. LLC v. Eli Lilly and Company 1:14-cv-00113?
A litigation summary depends on the asserted patent numbers, claim charts, and accused product(s). Without the docket’s complaint/amended complaint text and infringement contentions, the asserted estate cannot be identified.
Which Sanofi patents and which Lilly products were at issue
A defensible answer requires:
- asserted US patent publication or grant numbers
- instrumentality (drug, formulation, method-of-use, regimen)
- whether the case targeted ANDA/BLA submissions or was a stand-alone infringement suit.
Was the case driven by Paragraph IV, biosimilar pathways, or standalone infringement?
That requires the court filings or settlement references. Without docket extracts, pathway characterization cannot be verified.
What happened procedurally in Sanofi-Aventis v. Lilly (1:14-cv-00113): motions, claim construction, and trial outcomes?
A procedural analysis must track:
- case schedule (Rule 16 order, Markman/claim construction dates)
- dispositive motions (12(b)(6), summary judgment)
- infringement/invalidity rulings
- whether any ITC action paralleled the district court case.
Without the docket event list and orders, the procedural posture cannot be summarized.
Key events needed for litigation chronology
- complaint filing date and assignments
- amended complaint(s)
- scheduling order(s)
- claim construction order(s)
- any injunction or stay-related rulings
- final judgment or dismissal.
Which court handled 1:14-cv-00113 and what jurisdictional facts mattered?
A correct analysis requires:
- the district and judge
- venue and jurisdiction statements
- whether any stay was entered under patent case coordination doctrines
- any consolidation or related actions.
No jurisdictional facts were provided.
How strong was Sanofi’s patent position in 1:14-cv-00113 based on rulings?
Patent “strength” depends on:
- court findings on infringement
- findings on validity (novelty, obviousness, written description, enablement, indefiniteness)
- whether the court addressed specific claim limitations.
Without the orders, any strength rating would be non-factual.
Validity and infringement issues courts typically decide
- obviousness and motivation
- claim construction of critical limitations
- anticipation by prior art
- prosecution history estoppel or disclaimer.
Did Eli Lilly challenge validity via PTAB/Inter partes review (IPR), and how did that affect outcomes?
A complete assessment requires identifying:
- whether any asserted patents were subject to IPR petitions
- PTAB outcomes (institution and final written decisions)
- any district court stay and estoppel arguments.
No PTAB/ITC/litigation cross-links were provided.
Did the case end in settlement, consent judgment, or final adjudication?
Settlement and licensing outcomes require:
- settlement agreement date
- whether a consent judgment was entered
- whether any at-risk launch was permitted or blocked
- any associated licensing terms or stipulated dismissal language.
No disposition data is available.
What is the Orange Book status of the relevant Sanofi patents for 1:14-cv-00113?
Orange Book analysis requires:
- the listed drug (NDC)
- listed patent numbers and expiration dates
- which patents were listed as “drug substance,” “drug product,” and “methods of use”
- whether Lilly’s action matched a specific Orange Book listing.
No drug/NDC or patent list was provided.
What generic or biosimilar entry risks did 1:14-cv-00113 affect for Lilly or competitors?
Entry risk hinges on:
- whether the patents were listed on the Orange Book and matched the claims
- whether court rulings resolved infringement/validity for those claims
- whether a settlement triggered a specific “design-around” or launch date.
Without asserted patents and claims, entry risk cannot be computed.
How does Sanofi’s litigation strategy in 1:14-cv-00113 compare with other Sanofi vs. Lilly patent suits?
A comparison requires:
- target drug and patent family
- common asserted claim themes
- outcomes and typical remedies (injunction vs. damages vs. stipulated design-around).
No family linkage or comparative case identifiers were provided.
Key Takeaways
None provided. A factual litigation summary and analysis cannot be produced from the docket number alone without the underlying case record.
FAQs
- What is the full case caption and court/judge for Sanofi-Aventis U.S. LLC v. Eli Lilly and Company 1:14-cv-00113?
- Which specific US patents were asserted and what claims were targeted?
- Were any motions decided on claim construction or summary judgment?
- Did the parties enter a settlement, and did it affect launch timing for any generic applicants?
- Were any PTAB IPR proceedings filed for the asserted patents, and did they change district court strategy?
References (APA)
- Sanofi-Aventis U.S. LLC v. Eli Lilly and Company, No. 1:14-cv-00113 (district court docket).
